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Objectives The aim of this study was to determine which combination therapy in patients with hypertension and diabetes
most effectively decreases cardiovascular events.
Background The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic
Hypertension) trial compared the outcomes effects of a renin-angiotensin system blocker, benazepril, combined
with amlodipine (BA) or hydrochlorothiazide (BH). A separate analysis in diabetic patients was pre-specified.
Methods A total of 6,946 patients with diabetes were randomized to treatment with BA or BH. A subgroup of 2,842
diabetic patients at very high risk (previous cardiovascular or stroke events) was also analyzed, as were 4,559
patients without diabetes. The primary end point was a composite of cardiovascular death, myocardial infarc-
tion, stroke, hospitalization for angina, resuscitated arrest, and coronary revascularization.
Results In the full diabetes group, the mean achieved blood pressures in the BA and BH groups were 131.5/72.6
and 132.7/73.7 mm Hg; during 30 months, there were 307 (8.8%) and 383 (11.0%) primary events (hazard
ratio [HR]: 0.79, 95% confidence interval [CI]: 0.68 to 0.92, p  0.003). For the diabetic patients at very high
risk, there were 195 (13.6%) and 244 (17.3%) primary events (HR: 0.77, 95% CI: 0.64 to 0.93, p  0.007). In
the nondiabetic patients, there were 245 (10.8%) and 296 (12.9%) primary events (HR: 0.82, 95% CI: 0.69 to
0.97, p  0.020). In the diabetic patients, there were clear coronary benefits with BA, including both acute
clinical events (p  0.013) and revascularizations (p  0.024). There were no unexpected adverse events.
Conclusions In patients with diabetes and hypertension, combining a renin-angiotensin system blocker with amlodipine, com-
pared with hydrochlorothiazide, was superior in reducing cardiovascular events and could influence future man-
agement of hypertension in patients with diabetes. (Avoiding Cardiovascular Events Through COMbination Ther-
apy in Patients Living With Systolic Hypertension [ACCOMPLISH]; NCT00170950) (J Am Coll Cardiol 2010;56:
77–85) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.046B
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Hypertension Treatment in Patients With Diabetes June 29, 2010:77–85There are 2 critical parts to the
treatment of hypertension in pa-
tients with diabetes mellitus. Ac-
cording to contemporary guide-
lines, blood pressure should be
reduced to below 130/80 mm Hg
and the primary antihypertensive
drug should be a blocker of the
renin-angiotensin system (RAS), ei-
ther an angiotensin receptor blocker
or an angiotensin-converting en-
zyme (ACE) inhibitor (1,2).
Blockers of the RAS are known
o have cardiovascular and renal protective effects in diabetic
atients (3–6). For many patients, however, a single anti-
ypertensive agent is not sufficient to achieve blood pressure
ontrol, so a 2-drug combination is recommended as initial
herapy if the baseline blood pressure in diabetic patients is
50/90 mm Hg or higher (1,2). Furthermore, guidelines
uggest that a thiazide diuretic usually be combined with the
ngiotensin receptor blocker or ACE inhibitor (1). Diuret-
cs not only add antihypertensive efficacy when combined
ith RAS blockers but can also provide cardiovascular
rotection (7,8).
However, more recent evidence suggests that calcium
hannel blockers, amlodipine in particular, can reduce car-
iovascular events in patients with coronary disease or
igh-risk hypertension (9,10). Moreover, amlodipine may
ndependently add vasoprotective effects when combined
ith agents such as ACE inhibitors (11,12). To test the
elative merits of these 2 types of combination hyperten-
ion therapies, the ACCOMPLISH (Avoiding Cardio-
ascular Events Through COMbination Therapy in Pa-
ients Living With Systolic Hypertension) trial compared
reatment outcomes of ACE inhibitor  amlodipine and
CE inhibitor  hydrochlorothiazide combinations. This
rial was conducted in high-risk hypertensive patients and
ound that the amlodipine-based combination was more
ffective in reducing a composite of fatal and nonfatal
ardiovascular events (13).
There was a pre-specified plan in the ACCOMPLISH
rial to separately compare the outcomes effects of the 2
reatment strategies in patients with diabetes. This article
eports the results of this comparison, both in the full
iabetic patient cohort and additionally in very high risk
iabetic patients defined as those with histories of cardiac
vents, stroke, or renal disease. To provide a clinical context
or the diabetic patients, data from the nondiabetic hyper-
nd lecture fees from Novartis, Boehringer Ingelheim, Pfizer, and Merck. Roxzana
elly, Tsushung Hua, and Allen Hester are employed by Novartis Pharmaceuticals.
r. Pitt receives consulting fees from Novartis, Pfizer, Merck, Takeda, Bayer, Forest
aboratories, Sankyo, Ono, and AstraZeneca; has stock options from Relypsa,
G-Medicine, and Nile Therapeutics; and has received grants from Medtronic,
ayer, Novartis, and Abbott Laboratories.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BA  benazepril plus
amlodipine
BH  benazepril plus
hydrochlorothiazide
HR  hazard ratio
RAS  renin-angiotensin
systemu
Manuscript received November 11, 2009; revised manuscript received February 9,
010, accepted February 15, 2010.ensive patients studied in the ACCOMPLISH trial are
lso analyzed.
ethods
he ACCOMPLISH trial was designed to test the hypoth-
sis that a combination of an ACE inhibitor with amlodip-
ne would be superior to the combination of the same ACE
nhibitor with hydrochlorothiazide in reducing a composite
f cardiac and stroke events in high-risk hypertensive
atients. The full methods for this trial were described
reviously (13,14). A key pre-specified analysis for the study
as the comparison of the effects on end points of the
treatment arms in the diabetic patients included in this
rial. These results are the primary focus of this report.
rganization. The study was designed, supervised, ana-
yzed, and interpreted by the academic authors of the
resent report. The roles of key supporting committees were
escribed previously (13). The database of adjudicated end
oints was maintained at the Duke Clinical Research
nstitute.
atients. The study was performed in hypertensive patients
t high risk of cardiovascular and related events. The
nhanced risk in these patients was established by the
resence of previously established concomitant conditions,
n particular diabetes mellitus, coronary events, myocardial
nfarction, revascularization, stroke, impaired renal func-
ion, peripheral arterial disease, and left ventricular hyper-
rophy. Details of these criteria were described previously
13). The diagnosis of diabetes in the study patients was
ade clinically by the individual investigators. Data on
atients who satisfied the trial’s entry criteria but did not
ave diabetes were also analyzed.
tudy procedures. Immediately on establishing eligibility
nd entering the study, patients were randomly assigned to
of 2 treatment arms: either benazepril plus amlodipine
BA) or benazepril plus hydrochlorothiazide (BH). All
revious antihypertensive therapies were immediately discon-
inued and replaced by one of the study’s fixed combination
herapies. The starting doses were benazepril 20 mg/day
lus either amlodipine 5 mg/day or hydrochlorothiazide
2.5 mg/day. The study protocol then mandated an increase
n the benazepril dose to 40 mg/day in both treatment arms.
hereafter, the amlodipine dose could be increased to 10
g/day or the hydrochlorothiazide dose to 25 mg/day if
equired to achieve a target blood pressure goal of 140/90
m Hg. For the diabetic patients (who represent the
rincipal cohort of this report) or for patients with chronic
idney disease, a target blood pressure of 130/80 mm Hg
as recommended, but not mandated.
If needed for blood pressure control, investigators could
dd other antihypertensive agents (except ACE inhibitors,
ngiotensin receptor blockers, calcium-channel blockers, or
hiazide diuretics), including beta-blockers, clonidine,
lpha-blockers, and spironolactone. Investigators could also
se once-daily loop diuretics if in their clinical judgment
t
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June 29, 2010:77–85 Hypertension Treatment in Patients With Diabeteshese agents were required for volume management.
fter an initial 3-month period during which all the
ecessary blood pressure adjustments were made, patients
eturned for visits after an additional 3 months and then
t 6-month intervals until the end of the trial. Blood
ressure was measured by standard clinical trial method-
logy described previously (13).
nd points. The primary study end point was the time to
he first recorded event. This was defined as the composite
f the first occurrence of a cardiovascular event or death
rom cardiovascular causes. Death from cardiovascular
auses was defined as sudden death from cardiac causes or
eath from myocardial infarction, stroke, coronary interven-
ion, congestive heart failure, or other cardiovascular causes.
ardiovascular events were defined as myocardial infarction,
troke, hospitalization for unstable angina, coronary revas-
ularization, or resuscitation after cardiac arrest. Only the
rst event in an individual patient was counted in the
nalysis of the primary end point.
Independent of the calculation of the primary end point,
here were pre-specified analyses of the individual compo-
ents of the primary and secondary end points. In these
nalyses, events were counted without censoring for previ-
us occurrence of other end points. The secondary end
oint of the trial was a composite of cardiovascular death,
onfatal myocardial infarction, and nonfatal stroke. Other
re-specified end points included coronary revascularization
rocedures, unstable angina, hospitalization for heart fail-
re, progression of renal disease, and all-cause mortality. In
ddition, this report provides data on acute clinical nonre-
ascularization coronary end points (myocardial infarctions,
udden cardiac deaths, and hospitalizations for unstable
ngina). In a post hoc analysis, this report describes renal
vents defined as serum creatinine concentrations that
ncreased by at least 50% during the study (regardless of
heir study baseline values) and were above the normal
aboratory-defined range.
tatistical analysis. The power and sample size of the
tudy were originally calculated based on the entire study
ohort, with the intent that the ACCOMPLISH trial
ould have 90% power to detect a 15% reduction in risk for
he BA group, based on the assumption of a 3.5% annual
vent rate for the BH group. However, no such calcula-
ions were made purely for the patients with diabetes cohort
n this trial. Nevertheless, because the diabetic patients
epresented approximately 60% of the total patients enrolled
n the trial, it was considered appropriate to undertake the
re-specified analysis of this patient subgroup. In addition,
t was decided to analyze data in patients with diabetes who
dditionally had histories of cardiovascular or stroke events
referred to as diabetic patients at very high risk). To
rovide a clinical context for these data, analysis was also
erformed in the patients without diabetes enrolled in the
CCOMPLISH trial.
All study outcomes were adjudicated according to stan-ard criteria by a blinded clinical end points committee.
†nterim statistical analyses were performed at 6-month
ntervals for the data safety monitoring committee, which
as able to determine whether a difference in outcomes
xisted between the 2 treatment arms, without knowing the
dentity of the 2 treatment arms. The description of this
rocedure, together with a detailed explanation of the
pecified stopping rules for the trial, was given previously
13). This committee did recommend early termination of the
rial based on evidence that the criteria for satisfying the
topping rules had been met (13). All patients were included in
nalysis of the primary end point according to the intention-
o-treat principle. The primary comparison of the treatment
roups was based on a log rank test. Univariate Cox
egression (which included only treatment in the model)
as performed for the time to the first primary event to
btain the point estimate of the hazard ratio (HR) and its
5% confidence interval between the 2 treatment arms.
ndividual analyses were also performed for each component
f the primary end point, without censoring for previous
rimary events. Secondary and other efficacy end points
ere analyzed with the use of a similar log-rank test and
nivariate Cox regression analyses. Comparisons among
atient groups of clinical baseline and demographic data
aseline Characteristics of Patient SubgroupsTable 1 Baseline Characteristics of Patient Subgroups
Characteristic
No
Diabetes
All
Diabetes
High-Risk
Diabetes
Patients 4,559 6,946 2,842
Sex
Male 3,009 (66%)* 3,954 (57%) 1,830 (64%)†
Female 1,550 (34%)* 2,992 (43%) 1,012 (36%)†
Age (yrs) 69.8 (7.0)* 67.5 (6.6) 66.9 (7.2)†
65 yrs 3,344 (73)* 4,296 (62) 1,668 (59)†
Race
Caucasian 4,075 (89%)* 5,537 (80%) 2,277 (80%)
Black 374 (8%)* 1042 (15%) 429 (15%)
BP (mm Hg)
Systolic 145.6 (18.6) 145.2 (18.1) 144.8 (18.3)
Diastolic 81.1 (10.8)* 79.3 (10.6) 78.7 (10.8)†
Heart rate (beats/min) 67.9 (10.7)* 72.0 (10.9) 71.0 (10.8)†
Body mass index (kg/m2) 29.0 (5.3)* 32.2 (6.5) 32.2 (6.4)
Fasting blood glucose (mg/dl) 101.0 (17.2)* 144.7 (51.5) 146.4 (55.8)†
eGFR (ml/min) 76.5 (19.8)* 80.6 (22.2) 78.5 (23.4)†
Previous coronary artery
disease
3,298 (72%)* 2,016 (29%) 2,016 (71%)†
Previous stroke 941 (21%)* 557 (8%) 557 (20%)†
Chronic kidney disease 867 (19%)* 1,210 (18%) 617 (22%)†
Left ventricular hypertrophy 760 (17%)* 761 (11%) 396 (14%)†
BP medications
0† 128 (3%)† 193 (3%)† 59 (2%)†
1† 1,010 (22%)† 1,581 (23%)† 452 (16%)†
2 3,421 (75%)† 5,172 (75%)† 2,331 (82%)†
Lipid-lowering therapy 3,346 (73%)* 4,476 (64%) 2,192 (77%)†
Beta-blocker therapy 2,659 (58%)* 2,823 (41%) 1,582 (56%)†
Antiplatelet therapy 3,573 (79%)* 3,872 (56%) 2,106 (74%)†
alues are absolute numbers (%) or mean (SD). *Significant difference from the all diabetes cohort.
Significant difference from the non–high-risk members of the all diabetes cohort.
BP  blood pressure; eGFR  estimated glomerular filtration rate.
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BA  benazepril plus amlodipine; BH  benazepril plus hydrochlorothiazide; HCTZ 
hydrochlorothiazide.
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Hypertension Treatment in Patients With Diabetes June 29, 2010:77–85ere performed using t tests for continuous variables and
hi-square tests for categorical variables.
esults
total of 6,946 patients with hypertension and diabetes
ntered the trial; 3,478 were randomly assigned to the BA
roup and 3,468 to the BH group. There were 2,842
iabetic patients at very high risk (histories of cardiac,
troke, or renal events), of whom 1,432 were randomized to
A and 1,410 to BH. There were 4,559 patients
ithout diabetes at baseline, of whom 2,266 were random-
zed to BA and 2,293 to BH. There were no meaningful
ifferences in baseline clinical characteristics between the
A and BH treatment arms within any of the 3 patient
he Trial
etes, with diabetes, and with high-risk diabetes (as defined in the text) during the
Living With Systolic Hypertension) trial. Baseline blood pressures and patient
hydrochlorothiazide.Figure 1 Mean Blood Pressure Values in Patient Subgroups During t
Systolic and diastolic blood pressures during a 42-month period in patients without diab
ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients
numbers are given in Table 1. B  A  benazepril  amlodipine; B  H  benazepril omparison of Hypertension Treatment Stepsn Patients With Diab tesTable 2 Compariso of Hyper ension Treatment Stepsin Patients With Diabetes
Characteristic BA BH
Patients 3,478 3,468
Benazepril 40 mg/day 2,246 (65) 2,179 (63)
Amlodipine 5 mg/day or HCTZ 12.5 mg/day 637 (18) 634 (18)
Amlodipine 10 mg/day or HCTZ 25 mg/day 1,796 (52) 1,731 (50)
1 additional drug 854 (25) 836 (24)
2 additional drugs 598 (17) 603 (17)
Intensification of diabetes therapy 1,496 (43) 1,551 (45)
alues are absolute numbers (%). The types of additional antihypertensive drugs allowed in the
tudy are described in the text. Intensification of diabetes therapy after randomization included
nitiating drug therapy, increasing drug doses, and adding drugs. None of the differences between
he treatment groups was significant.
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June 29, 2010:77–85 Hypertension Treatment in Patients With Diabetesroups. The clinical characteristics of the study patients are
hown in Table 1.
For the full diabetes cohort, the mean duration of
reatment in the BA group was 29.7 and 29.5 months in
he BH group. Details of the final treatment regimens and
rug doses in the diabetic patients are shown in Table 2. For
he BA group, the mean doses were 36.6 mg for benaz-
pril and 7.9 mg for amlodipine; for the BH group, the
ean doses were 36.6 and 20.0 mg, respectively. The use of
dditional antihypertensive agents, as shown in Table 2, was
imilar in the 2 groups. Of the patients in this trial given
dditional drugs, selected at the discretion of the investiga-
ors, 65.2% received beta-blockers, 42.2% loop diuretics,
4.7% alpha-blockers, and 24.7% clonidine. The need for
dditional antidiabetes therapy during the trial also was
imilar in the 2 groups.
lood pressure. Almost all patients (97%) were already
eceiving antihypertensive drugs before entering the
tudy. Their blood pressures while receiving this previous
reatment are shown in Table 1 and were similar for the
treatment arms. Similarly, the effects of the study drugs
n blood pressure for the 2 treatment arms in the diabetic
atients were similar throughout the trial and are shown
n Figure 1. The mean value of blood pressures after the
reatment adjustments were completed were 131.5/72.6
m Hg in the BA arm and 132.7/73.7 mm Hg in the
H arm. The mean difference between the 2 arms
cross the study was 1.2/1.1 mm Hg. The attainment
f controlled blood pressure (130/80 mm Hg in these
iabetic patients, which was recommended to investiga-
ors but not mandated) was 45.9% in the BA arm and
3.7% in the BH arm.
A subgroup of 353 patients in the diabetes group under-
ent ambulatory blood pressure monitoring after 2 years of
tudy treatment. The data for systolic blood pressure are
hown in Table 3 and indicate that there were no significant
ifferences in 24-h, daytime or nighttime values between the
A and BH treatment arms.
tudy end points. The overall ACCOMPLISH trial was
topped early when the independent data safety monitoring
ommittee observed a difference in the incidence of the
rimary end point between the 2 study arms that exceeded the
re-specified stopping point and recommended termination of
4-h Systolic Blood Pressure Averagesn Patien s With DiabeteTable 3 24-h Systolic Blood Pressure Averagesin Patients With Diabetes
Characteristic BA BH
Mean
Difference p Value
Patients 185 168 — —
24-h mean 125.3 123.7 1.6 0.262
Daytime (6:00 AM–10:00 PM) 126.9 125.2 1.7 0.249
Nighttime (10:00 PM–6:00 AM) 119.9 118.9 1.0 0.528
ata obtained by ambulatory monitoring in patients with diabetes treated with BA or BH after
years of treatment.
Abbreviations as in Table 2.he trial. Details of this decision were described previously (13). wFor the diabetic patients as a whole, the time to the first
rimary end point in each treatment arm is shown in Figure 2.
his end point occurred in 307 (8.8%) patients in the BA
roup and 383 patients (11.0%) in the BH group, represent-
ng an absolute risk reduction of 2.2% and a hazard reduction
f 21% (HR: 0.79; p 0.003). The number needed to treat for
0 months (to save 1 primary end point) was 46. Data for other
ey end points for diabetic patients in this trial are shown in
able 4.
igh-risk diabetic patients. Because of the frequency of
revalent cardiovascular and renal disease in diabetic pa-
ients, further analyses were performed in those hyperten-
ive diabetic patients who had histories of coronary disease,
evascularization, stroke, peripheral arterial disease, or left
entricular hypertrophy (13).
Of the 2,842 such patients, 1,432 were randomized to
A treatment and 1,410 to BH treatment. The baseline
haracteristics of these patients are shown in Table 1. For
he high-risk diabetic patients randomized to BA, the
chieved mean doses of these agents were 36.6 mg and 7.8 mg,
espectively, and 98% received at least 1 additional antihyper-
ensive agent. For the BH arm, the mean doses were 36.4 mg
nd 19.9 mg, respectively. The effects of treatment on blood
ressure in these 2 study arms are shown in Figure 1. The
ean achieved blood pressures in the BA arm and BH
rm were 131.2/71.9 mm Hg and 132.4/73.3 mm Hg,
espectively; the mean difference was 1.2/1.4 mm Hg.
The time to the first primary end points in the 2 treatment
rms is shown in Figure 2. There were 195 events (13.6%) in
he BA arm and 244 events (17.3%) in the BH group,
epresenting an absolute risk reduction of 3.7% and a hazard
eduction of 23% (HR: 0.77, p 0.007). The number needed
o treat for 30 months to prevent 1 primary end point was 28.
lthough this number needed to treat in the high-risk diabetic
atients was lower than that for the non–high-risk diabetic
atients and the nondiabetic patients, the interactions for
reatment effect between these groups was not statistically signif-
cant. The other end points of interest are shown in Table 5.
ondiabetic patients. Of the 4,559 nondiabetic patients;
,266 were randomized to BA and 2,292 to BH.
aseline characteristics are shown in Table 1. Blood pres-
ure data are shown in Figure 1; the achieved mean blood
ressure values in the 2 treatment arms were 131.8/74.3 and
32.3/75.4 mm Hg, respectively. The end point data for the
treatment arms are shown in Figure 2 (primary end point)
nd Table 6 (all end points).
dverse events. For the 2 treatments arms in the total
iabetic cohort, and the nondiabetic cohort, the incidence
ates of the pre-specified adverse events are shown in Table 7.
rincipal metabolic changes in the 2 treatment arms for the
verall diabetic cohort are listed in Table 8.
iscussion
he analysis reported here indicates that in diabetic patients
ith hypertension the combination of an ACE inhibitor
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Hypertension Treatment in Patients With Diabetes June 29, 2010:77–85ith amlodipine is superior to the combination of the same
CE inhibitor with hydrochlorothiazide in reducing car-
iovascular outcomes. We observed that the size of this
ffect is similar to that in nondiabetic patients.
A further analysis in patients classified as those with
igh-risk diabetes, defined as patients with histories of
ardiovascular, stroke, and renal events in addition to their
iabetes, demonstrated a similar advantage for the combi-
ation of amlodipine with blockade of the RAS in reducing
he primary study end point. In fact, the number needed to
reat (to prevent 1 primary event over 30 months in the
Figure 2 Time to First Events in Major Patient Subgroups
Kaplan-Meier curves for time to the first primary composite end point in patients w
and with high-risk diabetes (as defined in the text). CV  cardiovascular; HR  ha
ardiovascular, Stroke, and Renal Outcomes in All Patients With DTable 4 Cardiovascular, Stroke, and Renal Outcomes in All Pat
Characteristic BA
Number of patients 3,478
Primary end point 307 (8.8)
Fatal and nonfatal myocardial infarction 77 (2.2)
Hospitalized unstable angina 23 (0.7)
Stroke 64 (1.8)
Cardiovascular death 62 (1.8)
Revascularization 180 (5.2)
Nonrevascularization coronary event* 111 (3.2)
Cardiovascular death  myocardial infarction  stroke 170 (4.9)
Hospitalized heart failure 74 (2.1)
All-cause death 141 (4.1)
Renal end point† 231 (6.6)alues are absolute numbers (%). *Myocardial infarction  unstable angina  sudden cardiac death. †
CI  confidence interval; other abbreviations as in Table 2.mlodipine arm compared with the hydrochlorothiazide
rm), which was 48 in the nondiabetic patients and 46 in the
verall diabetic cohort, was 28 in the high-risk diabetic
atients. Tests for the interactions between high-risk dia-
etic patients and either the non–high-risk diabetic patients
r the nondiabetic patients with treatment effect were not
tatistically significant. It was shown previously that high-
isk diabetic patients have an exaggerated probability of
ardiovascular events (15), so it is useful to note that the
enefit of the BA treatment in these patients was at least
s strong as in the other study groups.
diabetes, with diabetes,
tio; other abbreviations as in Figure 1.
esWith Diabetes
BH Hazard Ratio (95% CI) p Value
3,468 — —
383 (11.0) 0.79 (0.68–0.92) 0.003
91 (2.6) 0.85 (0.63–1.15) 0.283
36 (1.0) 0.64 (0.38–1.08) 0.092
70 (2.0) 0.91 (0.65–1.28) 0.607
74 (2.1) 0.84 (0.60–1.18) 0.312
224 (6.5) 0.80 (0.66–0.97) 0.024
151 (4.4) 0.73 (0.57–0.94) 0.013
203 (5.9) 0.84 (0.68–1.03) 0.085
67 (1.9) 1.11 (0.80v1.54) 0.545
139 (4.0) 1.02 (0.80–1.29) 0.887
422 (12.2) 0.53 (0.45–0.63) 0.001ithout
zard raiabetients50% increase in serum creatinine with final value above normal range.
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June 29, 2010:77–85 Hypertension Treatment in Patients With DiabetesIt should be noted that there were baseline differences,
ther than the presence or absence of diabetes, between the
iabetic and nondiabetic patients in the ACCOMPLISH
rial. The diabetic cohort included a higher proportion of
omen and black patients than the nondiabetic cohort; the
iabetic patients also had a lower prevalence of previous
oronary and stroke events and thus were less likely to be
eceiving therapies such as lipid-lowering agents, beta-
lockers, and antiplatelet drugs. However, as would be
xpected, the high-risk diabetic subgroup had the same
revious event profiles and adjunctive therapies as the
ondiabetic patients. As well, blood pressures and antihy-
ertensive therapies in the diabetic and nondiabetic groups
ere very similar to each other at baseline.
econdary end points. The ACCOMPLISH trial used a
road composite primary end point that incorporated fatal
nd nonfatal cardiovascular and stroke end points, including
oronary revascularization. The trial was terminated early
fter an interim data analysis revealed that there was a
ifference in event rates for the primary end point between
he BA and BH treatment arms. This early termination
f the trial limited its power to test fully the differing effects,
ardiovascular, Stroke, and Renal Outcomes in Patients With HighTable 5 Cardiovascular, Stroke, and Renal Outcomes in Patien
Characteristic BA
Number of patients 1,432
Primary end point 195 (13.6)
Fatal and nonfatal myocardial infarction 49 (3.4)
Hospitalized unstable angina 16 (1.1)
Stroke 38 (2.7)
Cardiovascular death 33 (2.3)
Revascularization 122 (8.5)
Nonrevascularization coronary event* 67 (4.7)
Cardiovascular death  myocardial infarction  stroke 99 (6.9)
Hospitalized heart failure 53 (3.7)
All-cause death 65 (4.5)
Renal end point† 134 (9.4)
alues are absolute numbers (%). *Myocardial infarction  unstable angina  sudden cardiac de
Abbreviations as in Tables 2 and 4.
ardiovascular, Stroke, and Renal Outcomes in Patients Without DTable 6 Cardiovascular, Stroke, and Renal Outcomes in Patien
Characteristic BA
Patients 2,266
Primary end point 245 (10.8)
Fatal and nonfatal myocardial infarction 48 (2.1)
Hospitalized unstable angina 21 (0.9)
Stroke 48 (2.1)
Cardiovascular death 45 (2.0)
Revascularization 154 (6.8)
Nonrevascularization coronary event* 83 (3.7)
Cardiovascular death  myocardial infarction  stroke 118 (5.2)
Hospitalized heart failure 26 (1.2)
All-cause death 95 (4.2)
Renal end point† 87 (3.8)alues are absolute numbers (%). *Myocardial infarction  unstable angina  sudden cardiac death. †
Abbreviations as in Tables 2 and 4.f any, of the 2 treatment regimens on some of the
mportant individual end points recorded in the trial.
Nevertheless, there were some noteworthy findings for
econdary end points. In the total diabetes cohort, there
ere significantly fewer coronary outcomes in the BA
rm. This applied to both acute clinical events (myocardial
nfarction, sudden cardiac death, and hospitalized unstable
ngina), which were reduced by 27%, and coronary revas-
ularization procedures, which were reduced by 20%. On
he other hand, heart failure rates were not different be-
ween the BA and BH treatment arms in either the
iabetic or nondiabetic cohorts. Previously, it had been
laimed that amlodipine, used as a monotherapy, may not
e an optimal therapy for heart failure prevention (8), but
his does not appear to be an issue when this drug is
ombined with a blocker of the RAS.
enal findings. Because virtually all patients were receiv-
ng blockers of the RAS before entering the study, the
reatinine-increasing effects of these agents were already
ncorporated into their baseline values, so that any further
ncreases likely reflected intrinsic changes in renal function.
e performed a post-hoc analysis based on the criteria of
Diabetesth High-Risk Diabetes
BH Hazard Ratio (95% CI) p Value
1,410 — —
244 (17.3) 0.77 (0.64–0.93) 0.007
60 (4.3) 0.80 (0.55–1.17) 0.246
26 (1.8) 0.60 (0.32–1.12) 0.107
41 (2.9) 0.91 (0.58–1.41) 0.664
42 (3.0) 0.77 (0.49–1.22) 0.265
149 (10.6) 0.80 (0.63–1.01) 0.060
99 (7.0) 0.66 (0.48–0.90) 0.008
124 (8.8) 0.78 (0.60–1.01) 0.062
44 (3.1) 1.18 (0.79–1.77) 0.405
76 (5.4) 0.84 (0.60–1.17) 0.292
204 (14.5) 0.62 (0.50–0.78) 0.001
50% increase in serum creatinine with final value above normal range.
esthout Diabetes
BH Hazard Ratio (95% CI) p Value
2,293 — —
296 (12.9) 0.82 (0.69–0.97) 0.020
68 (3.0) 0.70 (0.49–1.02) 0.059
23 (1.0) 0.91 (0.50–1.64) 0.749
63 (2.8) 0.76 (0.52–1.10) 0.147
60 (2.6) 0.75 (0.51–1.10) 0.137
162 (7.1) 0.95 (0.76–1.18) 0.630
106 (4.6) 0.78 (0.58–1.04) 0.084
161 (7.0) 0.73 (0.57–0.92) 0.008
29 (1.3) 0.89 (0.53–1.52) 0.679
123 (5.4) 0.77 (0.59–1.00) 0.052
221 (9.6) 0.38 (0.30–0.49) 0.001-Riskts Wiiabetts Wi50% increase in serum creatinine with final value above normal range.
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Hypertension Treatment in Patients With Diabetes June 29, 2010:77–85erum creatinine concentrations that increased by at least
0% during the trial (regardless of their baseline values) and
ere also above the laboratory-defined normal range. This
linically relevant index of renal disease progression was
7% lower in the BA than the BH arm in the diabetic
ohort. It was similarly lower in the high-risk diabetic
ubgroup (38%) and in the nondiabetic patients (62%).
hese findings, although significant and clinically informa-
ive, were not produced by a pre-specified trial analysis and
o should be regarded as exploratory rather than definitive.
till, they deserve further study in future trials.
ontrol of blood pressure. In designing this trial, hydro-
hlorothiazide was selected as the diuretic in the comparator
ombination because it is overwhelmingly the most widely
sed thiazide agent in clinical practice. It could be noted,
owever, that chlorthalidone was the diuretic used in some
revious hypertension trials (7,8) and is a more potent and
ong-acting agent than hydrochlorothiazide (16). Even so,
n the doses used in this trial, hydrochlorothiazide combined
ith an ACE inhibitor provided powerful blood pressure
ontrol that was similar to that observed in the ACE inhibitor–
mlodipine treatment arm. Furthermore, there was no differ-
nce between the 2 treatment arms in the number of dose
itrations or add-on drugs required to achieve these blood
ressures.
dverse Events During Treatmentn Pati nts With or Without DiabetesTable 7 Adverse Events uring Treatmentin Patients With or Without Diabetes
Characteristic
Diabetes Cohort Nondiabetes Cohort
BA BH BA BH
Patients 3,473 3,466 2,267 2,291
Peripheral edema 1,159 (33.4) 566 (16.3) 633 (27.9) 206 (9.0)
Dry cough 711 (20.5) 764 (22.0) 466 (20.6) 456 (19.9)
Dizziness 657 (18.9) 781 (22.5) 532 (23.5) 689 (29.7)
Hypotension 78 (2.2) 99 (2.9) 64 (2.8) 109 (4.5)
Angioedema 33 (1.0) 19 (0.5) 20 (1.0) 15 (0.7)
Hyperkalemia 23 (0.7) 26 (0.8) 11 (0.5) 7 (0.3)
Hypokalemia 3 (0.1) 12 (0.3) 0 (0.0) 5 (0.2)
ata for patients with or without diabetes treated with BA or BH. Values are absolute
umbers (%).
Abbreviations as in Table 2.
etabolic and Renal Measurements During Treatment in PatientsTable 8 Metabolic and Renal Measurements During Treatment
Characteristic
BA
Baseline
Fasting blood glucose (mg/dl) 145.2 (52.4)
Serum potassium (mM) 4.31 (0.42) 0
Serum creatinine (mg/dl) 0.97 (0.28) 0
eGFR (ml/min) 80.3 (22.1) 
Urinary albumin/creatinine ratio (mg/g) 224.8 (484.2) 9
LDL cholesterol (mg/dl) 101.3 (32.6) 1
HDL cholesterol (mg/dl) 48.2 (13.0) 0
Triglycerides (mg/dl) 178.0 (114.5) 2ll measurements are mean (SD). *p values are for differences between changes in the 2 treatments.
LDL  low-density lipoprotein; HDL  high-density lipoprotein; other abbreviations as in Tables 1 and 2These findings were confirmed by an ambulatory blood-
ressure monitoring substudy performed after 2 years of
tudy treatment. The hydrochlorothiazide combination was
t least as efficacious in reducing systolic blood pressure as
he amlodipine combination, both during the nighttime
s well as the daytime hours, thus indicating similar dura-
ions of action in the 2 treatment arms.
Metabolic and safety findings in this trial reflected the
nown properties of the drugs. There was no difference
etween the treatment groups in ACE inhibitor–related
ough, but there was a greater incidence of peripheral edema in
he amlodipine combination and a slightly greater incidence of
ypokalemia in the hydrochlorothiazide combination. Despite
hese apparently minimal differences, we cannot exclude the
ossibility that some as-yet unidentified effect of the thiazide
ay have made it less effective in reducing clinical end points
han the calcium channel blocker.
tudy limitations. There may be inadequate patient
umbers in subgroups of clinical trials to allow adequate
nalysis of outcomes, but in the present report the cohort
f patients with diabetes was sufficiently large to explore
he relevant events. It should be noted, however, that the
nalysis of the high-risk diabetic patients was not pre-
pecified, but was undertaken to test whether the out-
omes in these vulnerable patients were similar to the full
iabetes group.
Our use of 2 types of composite coronary end points,
amely nonrevascularization events (sudden cardiac death,
yocardial infarction, and unstable angina) or revascular-
zation procedures, was also not pre-specified. Our intention
n establishing these categories was to examine the rate of
ard clinical end points independently of the more elective
oronary interventions. Likewise, as discussed earlier, the
se of the renal end point (increase in creatinine) was not
riginally planned. Still, we believe that this exploratory
nding is of clinical interest and serves to support the
bservation—shown in our table of metabolic and renal
easurements—of the divergent effects of amlodipine and
ydrochlorothiazide therapies on renal function and
lbuminuria.
Diabetestients With Diabetes
BH
p Value*e Baseline Change
.5) 144.1 (50.6) 0.11 (59.2) 0.150
47) 4.30 (0.41) 0.03 (0.48) 0.001
34) 0.97 (0.27) 0.15 (0.32) 0.001
.5) 80.9 (22.3) 9.9 (17.6) 0.001
8.0) 232.4 (493.3) 20.1 (503.6) 0.001
.8) 100.8 (32.1) 11.2 (32.9) 0.489
9) 48.4 (13.4) 1.2 (9.0) 0.001
.8) 177.3 (121.8) 11.9 (105.4) 0.001Within Pa
Chang
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June 29, 2010:77–85 Hypertension Treatment in Patients With Diabetesonclusions
he combination of an ACE inhibitor with amlodipine,
ompared with its combination with hydrochlorothiazide,
as more effective in preventing fatal and nonfatal cardio-
ascular outcomes in hypertensive diabetic patients. This
nding was particularly evident in a subgroup of high-risk
iabetic patients with histories of cardiovascular, stroke, and
enal events and appeared to be independent of hemody-
amic effects. Patients receiving the amlodipine combina-
ion were more likely to experience peripheral edema, but
ther safety and metabolic findings were not meaningfully
ifferent between the treatments. For the large proportion
f diabetic patients whose blood pressure can be controlled
ith a 2-drug combination, the use of amlodipine with a
locker of the RAS should now be considered.
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